Reaction: Mirabegron to 1 product
- Reaction
- Reaction type
- glucuronidation; oxidation
- Direction
- Major circulating metabolite?
- No
- Spontaneous?
- No
- Activity
- unknown
- References
- Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T: Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012 Apr;40(4):815-24. doi: 10.1124/dmd.111.043588. Epub 2012 Jan 23. [Article]
- Konishi K, Tenmizu D, Takusagawa S: Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective beta3-Adrenoceptor Agonist, in Human Liver Microsomes. Eur J Drug Metab Pharmacokinet. 2018 Jun;43(3):301-309. doi: 10.1007/s13318-017-0450-x. [Article]
- FDA Approved Drug Products: MYRBETRIQ (mirabegron) extended-release tablets or granules, for oral use [Link]
- Comments
- Not Available
- Enzymes
Enzyme Km Vmax Role Cytochrome P450 3A4 Not Available Not Available implied Cytochrome P450 2D6 Not Available Not Available implied UDP-glucuronosyltransferase 2B7 Not Available Not Available implied UDP-glucuronosyltransferase 1-3 Not Available Not Available implied UDP-glucuronosyltransferase 1-8 Not Available Not Available implied